CSPC Pharmaceutical Group's High-Potency Amylin Receptor Agonist (SYH2092 Injection) Approved for Clinical Trials in China

Zhitong Finance APP News: CSPC (01093) announced that the SYH2092 injection developed by the Group has been approved by the China National Medical Products Administration to conduct clinical trials in China.

This product is an amylin receptor agonist. By optimizing agonist activity, it is expected to enhance efficacy while maintaining manageable tolerability. Furthermore, through optimized fatty acid modification, the product can prolong its in vivo half-life and has the potential to deliver sustained weight loss benefits.

Preclinical studies demonstrate that this product exhibits higher target agonist activity, significant weight loss effects, and sustained weight maintenance compared to multiple amylin analogs currently in clinical development. Furthermore, when used in combination with the Group’s self-developed dual biased agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, it shows synergistic weight loss effects, enhancing the magnitude of weight reduction while prolonging the duration of efficacy.

This product is expected to deliver significant clinical benefits in weight management for patients with obesity and improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM).